A new market study, titled “Global Diabetic Nephropathy Market Size, Status and Forecast 2019-2025” has been featured on WiseGuyReports.
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.
North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.
Growing prevalence of diabetes and obesity, increasing R&D investments in drug discovery and development, and rising awareness about diabetes and kidney-related disorders are some of the major drivers of the diabetic nephropathy market. On the other hand, stringent regulatory requirements and longer approval time for drugs as well as a lack of comprehensive therapeutic management for diabetic nephropathy are major concerns for the market. Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market is the recent market trends that have been observed in diabetic nephropathy market.
The global Diabetic Nephropathy market size set to grow with high CAGR value during 2019-2025.
This report focuses on the global Diabetic Nephropathy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Diabetic Nephropathy development in United States, Europe and China.
The key players covered in this study
Mitsubishi Tanabe Pharma
Market segment by Type, the product can be split into
Calcium Channel Blockers(CCBs)
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
G Protein-Coupled Receptors (GPCRs)
Market segment by Application, split into
Cancer Research Institutes
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Diabetic Nephropathy status, future forecast, growth opportunity, key market and key players.
To present the Diabetic Nephropathy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Diabetic Nephropathy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
2 Global Growth Trends
3 Market Share by Key Players
4 Breakdown Data by Type and Application
5 United States
9 Southeast Asia
11 Central & South America
12 International Players Profiles
13 Market Forecast 2019-2025
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)